ArticleFrontiers in immunology2019
An
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 49 citations in OpenAlex.
- Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC.Cell genomics · 2026Article
- A KRASMolecular therapy. Oncology · 2025Article
- Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.Journal of molecular medicine (Berlin, Germany) · 2025Article
- nuTCRacker: Predicting the Recognition of HLA-I-Peptide Complexes by αβTCRs for Unseen Peptides.European journal of immunology · 2025Article
- Enhanced mutanome analysis towards the induction of neoepitope-reactive T-cell responses for personalized immunotherapy of pancreatic cancer.Journal for immunotherapy of cancer · 2025Article
- Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing.Nature communications · 2024Article
- Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.Nature communications · 2023Article
- TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.Genomics, proteomics & bioinformatics · 2023Article
- InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides.Scientific data · 2023Article
- Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy.Annual review of cancer biology · 2023Article
- An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Predicting the Success of Fmoc-Based Peptide Synthesis.ACS omega · 2022Article
- Article
- Review
- Physicochemical Heuristics for Identifying High Fidelity, Near-Native Structural Models of Peptide/MHC Complexes.Frontiers in immunology · 2022Article
- Neo-Splicetopes in Tumor Therapy: A Lost Case?Frontiers in immunology · 2022Review
- Article
- Structural aspects of chemical modifications in the MHC-restricted immunopeptidome; Implications for immune recognition.Frontiers in chemistry · 2022Review
- Mechanistic diversity in MHC class I antigen recognition.The Biochemical journal · 2021Review
- Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.Nature communications · 2021Article
Corrections and comments
- Commented on byCommentary: An2021
- Commented on by
- Commented on by
Authors and funding
13 authors at 4 institutions in 5 countries.
Michele MishtoCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.
Artem MansurkhodzhaevQuantitative and Systems Biology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.
Ge YingDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Aruna BitraDivision of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Robert A CordfunkeDepartment of Immunohematology and Bloodbank, Leiden University Medical Center LUMC, Leiden, Netherlands.
Sarah HenzeQuantitative and Systems Biology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.
Debdas PaulQuantitative and Systems Biology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Henning UrlaubBioanalytical Mass Spectrometry Group, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Germany.
Jacques NeefjesDepartment of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center LUMC, Leiden, Netherlands.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States.
Dirk M ZajoncDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, CA, United States.
Juliane LiepeQuantitative and Systems Biology, Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.
La Jolla Institute for Immunology · USMax Planck Institute for Biophysical Chemistry · DELeiden University Medical Center · NLKing's College London · GB
Funding
Development of a pipeline tool to predict immunogenicity of cancer neo-epitopesR21AI134127 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN, SETTE, ALESSANDRO · 2018 to 2019
$495kCancer Research UKNIAID NIH HHS R21 AI134127
Abstract
Targeting CD8
Indexed as
Alternative SplicingComputational BiologyEpitope MappingAmino Acid SequenceAntigens, NeoplasmBinding SitesEpitopesGene Expression Regulation, NeoplasticHLA-A AntigensHumansModels, MolecularMolecular ConformationNeoplasmsPeptidesProteasome Endopeptidase ComplexProtein BindingAntigens, NeoplasmEpitopesHLA-A AntigensKRAS protein, humanPeptidesProteasome Endopeptidase ComplexProto-Oncogene Proteins p21(ras)adoptive T cell therapy targetsantigen presentationcancer epitopesKRASpeptide splicingproteasometumor immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.